Journal of Applied Smart HealthCare Informatics

Investigating the Molecular Pathways of Neuronal Apoptosis and Necroptosis in Response to Peripheral Nerve Injury and Neuropathic Pain

Clarisse Mendoza, and Cristina Reyes

This manuscript was compiled on October 4, 2024

Abstract

Neuropathic pain, a chronic pain state resulting from peripheral nerve injury, involves complex cellular and molecular mechanisms, including the activation of neuronal cell death pathways. Two major forms of programmed cell death—apoptosis and necroptosis—play critical roles in the progression of neuronal damage and the persistence of pain. Apoptosis, characterized by caspase activation and cellular shrinkage, serves as a controlled mechanism for eliminating damaged neurons, but its excessive activation can lead to significant neuronal loss in the dorsal root ganglia (DRG) and spinal cord. Necroptosis, a form of regulated necrosis driven by receptor-interacting protein kinases (RIPK1 and RIPK3), results in cell membrane rupture and the release of damage-associated molecular patterns (DAMPs) that can exacerbate inflammation and pain. The balance between apoptosis and necroptosis is influenced by various signaling pathways, including the tumor necrosis factor (TNF) signaling cascade, mitochondrial dysfunction, and the activation of the c-Jun N-terminal kinase (JNK) pathway. This review explores the molecular mechanisms underlying neuronal apoptosis and necroptosis in the context of peripheral nerve injury and neuropathic pain. We examine the roles of key regulatory proteins such as caspases, RIPKs, and mixed lineage kinase domain-like protein (MLKL) in driving these cell death processes. Additionally, we discuss potential therapeutic strategies targeting these pathways to preserve neuronal survival and alleviate chronic pain. Understanding the interplay between apoptosis and necroptosis in response to nerve injury may provide new insights into the development of treatments for neuropathic pain and improve outcomes for affected patients.

Keywords: *apoptosis, caspases, JNK pathway, mitochondrial dysfunction, necroptosis, RIPK1, TNF signaling*

Received: January 10, 2024 **Revised:** March, 16, 2024 **Accepted:** October, 2, 2024 **Published:** October, 4, 2024

1. Introduction

Neuropathic pain arises from injury or disease affecting the somatosensory nervous system, resulting in chronic pain states characterized by spontaneous pain, hyperalgesia (exaggerated response to painful stimuli), and allodynia (painful response to normally non-painful stimuli). A key feature of neuropathic pain is the progressive degeneration of neurons, particularly in the dorsal root ganglia (DRG) and spinal cord, where the loss of neuronal cells contributes to altered pain processing and the persistence of pain. Among the mechanisms driving neuronal loss, apoptosis and necroptosis—two forms of programmed cell death—are particularly important in determining the fate of neurons after nerve injury.

Apoptosis is a highly regulated form of cell death that involves the activation of caspases, a family of proteolytic enzymes that dismantle cellular components in an orderly manner, preventing the release of intracellular contents and subsequent inflammation. The intrinsic pathway of apoptosis is initiated by mitochondrial dysfunction, leading to the release of cytochrome c and the formation of the apoptosome, which activates caspase-9 and downstream effector caspases like caspase-3. The extrinsic pathway, in contrast, is triggered by the activation of death receptors, such as Fas or TNFR1, which recruit and activate caspase-8. Apoptosis is triggered in response to a variety of stress signals, including DNA damage, oxidative stress, and mitochondrial dysfunction, which are common in neurons following peripheral nerve injury. While apoptosis is essential for eliminating damaged cells and maintaining tissue homeostasis, its dysregulation can result in excessive neuronal loss, contributing to the progression of neuropathic pain and the reduction of neuronal circuits that modulate pain perception.

Necroptosis, in contrast, is a form of regulated necrosis that occurs when apoptosis is inhibited or when cells receive specific signals through death receptors such as TNFR1. Necroptosis is characterized by the activation of receptor-interacting protein kinase 1 (RIPK1) and RIPK3, leading to the phosphorylation of mixed lineage kinase domain-like protein (MLKL). Phosphorylated MLKL translocates to the plasma membrane, where it forms pores, resulting in loss of membrane integrity, cell swelling, and subsequent cell lysis. Unlike apoptosis, necroptosis leads to the release of damage-associated molecular patterns (DAMPs), such as HMGB1 and ATP, which can initiate an inflammatory response. This inflammation further exacerbates neuroinflammation in the DRG and spinal cord, contributing to pain hypersensitivity and the chronicity of neuropathic pain.

The dual roles of apoptosis and necroptosis in neuropathic pain underscore the complexity of cell death regulation following nerve injury. Both forms of cell death are tightly regulated by overlapping signaling pathways, including TNF signaling, mitochondrial pathways, and the JNK (c-Jun N-terminal kinase) cascade. TNF signaling, for instance, can initiate either apoptotic or necroptotic cell death depending on the cellular context and the presence of specific downstream molecules, such as FLIP (FLICE-like inhibitory protein) or caspase-8. Mitochondrial pathways play a crucial role in both intrinsic apoptosis and the amplification of necroptosis-related signals, particularly through the generation of reactive oxygen species (ROS) and the release of pro-apoptotic factors. The JNK cascade, which is activated by cellular stress, can promote both apoptotic and necroptotic pathways by modulating the expression of pro-death genes and influencing mitochondrial dynamics.

In this review, we explore the molecular pathways that regulate neuronal apoptosis and necroptosis in response to peripheral nerve injury. We focus on the key signaling molecules and pathways, including TNF signaling, mitochondrial pathways, and the JNK cascade, that influence these cell death processes. We also discuss potential therapeutic strategies aimed at modulating apoptosis and necroptosis to reduce neuronal damage and alleviate chronic pain. These strategies include the use of caspase inhibitors, RIPK1 inhibitors, and mitochondrial protectants that target the key mediators of cell death. Understanding the mechanisms underlying these forms of

Table 1. Key Differences Between Apoptosis and Necroptosis in Neuronal Degeneration

Form of Cell Death	Mechanism	Effect on Inflammation	Role in Neuropathic Pain
Apoptosis	Activation of caspases (e.g., caspase-3, -8, -9); Mitochondrial release of cytochrome c	Non-inflammatory due to controlled cell dismantling	Contributes to neuronal loss but limits inflammation
Necroptosis	Activation of RIPK1, RIPK3, and MLKL; Disruption of membrane integrity	Highly inflammatory due to release of DAMPs	Exacerbates neuroinflammation and pain persistence

Table 2. Therapeutic Targets for Modulating Apoptosis and Necroptosis in Neuropathic Pain

Target	Mechanism of Action	Potential Benefits	Current Challenges
Caspase Inhibitors	Inhibit caspase activity, preventing apoptosis	Reduces neuronal loss and preserves synaptic connections	Risk of impairing normal apoptotic processes
RIPK1 Inhibitors	Block RIPK1 activity, preventing necroptosis initiation	Decreases neuroinflammation and reduces release of DAMPs	Requires careful dosing to avoid immune suppression
Mitochondrial Protectants (e.g., antioxidants)	Reduce oxidative stress and mitochondrial dysfunction	Protects neurons from apoptosis and necroptosis	Limited ability to cross the blood-brain barrier

cell death may offer new avenues for managing neuropathic pain and improving neuronal survival, thus providing a better quality of life for patients suffering from chronic pain conditions.

Both apoptosis and necroptosis play critical roles in shaping the response of neurons to injury and determining the extent of neuronal loss and inflammation. Targeting these pathways to modulate their activity offers a promising therapeutic strategy for reducing the burden of chronic neuropathic pain. Strategies that inhibit excessive apoptosis could prevent unnecessary neuronal loss, while therapies that block necroptosis could mitigate the inflammatory response that contributes to pain hypersensitivity. By understanding the balance between these cell death processes, it may be possible to develop more targeted and effective interventions that not only reduce pain but also preserve neuronal function.

2. Molecular Pathways of Neuronal Apoptosis

2.1. Intrinsic Pathway of Apoptosis: The Role of Mitochondria

The intrinsic pathway of apoptosis, also known as the mitochondrial pathway, is initiated by intracellular stress signals such as DNA damage, oxidative stress, and calcium dysregulation, which are common in neurons following peripheral nerve injury. This pathway is regulated by the Bcl-2 family of proteins, which includes both pro-apoptotic (e.g., Bax, Bak) and anti-apoptotic (e.g., Bcl-2, Bcl-xL) members. Upon activation of pro-apoptotic signals, Bax and Bak undergo conformational changes and integrate into the mitochondrial outer membrane, leading to mitochondrial outer membrane permeabilization (MOMP).

MOMP results in the release of cytochrome c from the mitochondria into the cytosol, where it binds to Apaf-1 (apoptotic protease activating factor-1) to form the apoptosome. The apoptosome recruits and activates caspase-9, which in turn activates downstream executioner caspases, such as caspase-3 and caspase-7. These executioner caspases cleave various cellular substrates, leading to DNA fragmentation, cytoskeletal breakdown, and eventual cell death. This process ensures that damaged cells are dismantled in a controlled manner, minimizing inflammation and preventing the release of intracellular contents that could trigger immune responses.

Mitochondrial dysfunction following nerve injury can also increase the production of reactive oxygen species (ROS), which further damage mitochondrial DNA and proteins, amplifying apoptotic signals. The accumulation of ROS leads to oxidative stress, which can disrupt the integrity of the mitochondrial membrane and enhance the activation of pro-apoptotic factors like Bax. This creates a feedback loop that accelerates the apoptotic process, leading to widespread neuronal loss. Modulating the balance between pro- and anti-apoptotic Bcl-2 family members or targeting mitochondrial ROS production has been proposed as a therapeutic strategy to reduce apoptosis and preserve neuronal survival in neuropathic pain conditions. Agents such as Bcl-2 mimetics or antioxidants like coenzyme Q10 have shown promise in preclinical models by tipping the balance towards neuronal survival.

2.2. Extrinsic Pathway of Apoptosis: Death Receptor Signaling

The extrinsic pathway of apoptosis is initiated by the activation of death receptors on the cell surface, such as TNFR1, Fas, and TRAIL receptors, which are members of the tumor necrosis factor receptor superfamily. Binding of ligands like TNF-α or Fas ligand (FasL) to these receptors recruits adaptor proteins such as FADD (Fas-associated death domain) and leads to the formation of the death-inducing signaling complex (DISC). DISC facilitates the activation of initiator caspase-8, which directly activates downstream executioner caspases, such as caspase-3. This pathway allows for the rapid response to extracellular signals that mark cells for apoptosis, ensuring that damaged or potentially harmful cells are eliminated efficiently.

In neurons, the extrinsic pathway is often modulated by the cellular context and the presence of anti-apoptotic signals. For example, neuronal cells may upregulate anti-apoptotic proteins like FLIP (FLICE-like inhibitory protein) to inhibit caspase-8 activation, shifting the balance towards survival. This regulation is critical in maintaining neuronal integrity, as excessive activation of death receptor pathways could lead to unwarranted neuronal loss. However, in the presence of persistent inflammation, as seen in neuropathic pain, TNF-α signaling can overwhelm these protective mechanisms, leading to apoptosis. Chronic exposure to inflammatory cytokines can sensitize neurons to death receptor signaling, making them more susceptible to apoptosis even under conditions where survival signals are present.

Therapeutic inhibition of death receptor signaling or caspase-8 activation has shown potential in reducing neuronal apoptosis and alleviating pain in preclinical models. For instance, blocking TNFR1 activation or using caspase-8 inhibitors can prevent the apoptotic signaling cascade, thereby reducing neuronal loss and preserving pain-modulatory pathways in the spinal cord and DRG. These approaches aim to balance the need for eliminating damaged cells with the preservation of functional neuronal circuits that are essential for proper sensory processing.

The intrinsic and extrinsic pathways of apoptosis are tightly inter-

Table 3. Key Regulators of the Intrinsic Apoptosis Pathway in Neurons

Regulator	Role in Apoptosis	Mechanism	Potential Therapeutic Targeting
Bax/Bak	Promotes mitochondrial outer membrane permeabilization (MOMP)	Forms pores in the mitochondrial membrane, leading to cytochrome c release	Inhibition could prevent apoptosis initiation and protect neurons
Bcl-2/Bcl-xL	Inhibits MOMP and stabilizes mitochondrial integrity	Binds to and inhibits pro-apoptotic proteins like Bax	Bcl-2 mimetics could enhance neuronal survival by reinforcing anti-apoptotic signaling
Cytochrome c	Activates caspase-9 by forming the apoptosome with Apaf-1	Triggers caspase cascade leading to cell dismantling	Targeting apoptosome formation may reduce excessive apoptosis

Table 4. Key Components of the Extrinsic Apoptosis Pathway in Neuronal Cells

Component	Function in Apoptosis	Mechanism of Action	Therapeutic Targeting
TNFR1	Initiates apoptotic signaling through death domain interactions	Recruits FADD and forms DISC to activate caspase-8	TNFR1 antagonists could reduce inflammation-driven neuronal apoptosis
Caspase-8	Key initiator caspase in the extrinsic pathway	Activates executioner caspases like caspase-3, leading to apoptosis	Caspase-8 inhibitors may prevent excessive cell death
FLIP	Inhibits caspase-8 activation by competing for binding at the DISC	Modulates the sensitivity of neurons to death receptor signaling	Enhancing FLIP expression could promote neuronal survival

connected, and their regulation determines the fate of neurons in response to injury. While the intrinsic pathway responds to intracellular damage and stress, the extrinsic pathway is more responsive to extracellular cues from the surrounding environment, such as inflammatory cytokines. Understanding the crosstalk between these pathways and their role in neuronal degeneration is essential for developing targeted therapies that can mitigate neuronal loss and alleviate the chronic pain associated with nerve injury.

3. Necroptosis: A Form of Regulated Necrosis in Neuronal Injury

3.1. Mechanisms of Necroptosis: RIPK1, RIPK3, and MLKL

Necroptosis is initiated when death receptors like TNFR1 are activated in conditions where caspase-8 activity is inhibited or insufficient, allowing the assembly of a necrosome complex consisting of receptor-interacting protein kinase 1 (RIPK1) and receptor-interacting protein kinase 3 (RIPK3). The necrosome serves as a signaling hub where RIPK1 and RIPK3 interact and undergo mutual phosphorylation, a critical step that stabilizes the complex and facilitates downstream signaling events. This interaction is mediated through their RIP homotypic interaction motifs (RHIM), which allows them to form filamentous structures resembling amyloid fibrils. These amyloid-like complexes enhance the stability of the necrosome, providing a scaffold for the subsequent recruitment and activation of downstream effectors, such as the mixed lineage kinase domain-like protein (MLKL). Once activated through phosphorylation by RIPK3, MLKL undergoes a conformational change, which is essential for its translocation to the plasma membrane.

Phosphorylated MLKL oligomerizes and integrates into the plasma membrane, forming pores that disrupt the membrane's structural integrity. This disruption results in an influx of ions and water, causing cellular swelling, membrane rupture, and ultimately, necrotic cell death. The loss of membrane integrity leads to the release of intracellular contents, including various damage-associated molecular patterns (DAMPs), into the extracellular space. The release of DAMPs, such as high-mobility group box 1 (HMGB1), ATP, and mitochondrial DNA, serves as a danger signal to the surrounding environment. These DAMPs are potent inducers of inflammation and act by binding to pattern recognition receptors (PRRs) like Toll-like receptors (TLRs) and NOD-like receptors (NLRs), which are expressed on immune cells and surrounding glial cells.

The activation of TLRs and NLRs by DAMPs triggers a robust inflammatory response, characterized by the activation of downstream signaling pathways such as NF-κB and mitogen-activated protein kinases (MAPKs). These pathways drive the production of pro-inflammatory cytokines, chemokines, and other mediators that amplify the immune response. In the context of the central nervous system (CNS), DAMPs released due to necroptosis can activate glial cells, including microglia and astrocytes, which play pivotal roles in maintaining the inflammatory milieu. This inflammatory cascade is particularly significant in neuroinflammation, where the sustained activation of glial cells can lead to the chronic release of cytokines such as TNF-α, interleukin-1β (IL-1β), and interleukin-6 (IL-6). These cytokines contribute to the sensitization of neuronal pathways, promoting a heightened pain response and exacerbating neuronal damage over time.

The inflammatory response induced by necroptosis in the CNS is tightly associated with the development and maintenance of chronic pain, especially in conditions like neuropathic pain. Neuropathic pain results from injury or dysfunction within the nervous system, often characterized by hyperalgesia and allodynia, which are enhanced sensitivity to painful and non-painful stimuli, respectively. In the spinal cord and dorsal root ganglia (DRG), the release of DAMPs and the activation of PRRs on glial cells establish a localized pro-inflammatory environment that facilitates the transition from acute

Component	Role in Necroptosis	Mechanism of Action
RIPK1	Scaffold protein that initiates necrosome formation	Interacts with RIPK3 through RHIM domains to form a stable complex
RIPK3	Activator of MLKL	Phosphorylates MLKL, leading to its activation and oligomerization
MLKL	Effector of necroptosis	Forms membrane-disrupting pores, leading to cell lysis
DAMPs	Pro-inflammatory mediators	Released upon membrane rupture; activate TLRs and NLRs on surrounding cells

Table 5. Key Components of the Necroptosis Pathway and Their Functions

Neurodegenerative Condition	Role of Necroptosis	Inflammatory Consequences
Multiple Sclerosis (MS)	Necroptotic death of oligodendrocytes	Contributes to demyelination and influx of immune cells
Alzheimer's Disease (AD)	Necroptosis of neurons in response to amyloid-beta toxicity	Amplifies microglial activation and plaque formation
Amyotrophic Lateral Sclerosis (ALS)	Motor neuron death through necroptotic pathways	Enhances neuroinflammation, contributing to motor dysfunction

Table 6. Role of Necroptosis in Neurodegenerative Diseases

to chronic pain. Microglia, the resident immune cells of the CNS, become activated in response to DAMP signaling and produce neurotoxic factors such as reactive oxygen species (ROS) and nitric oxide (NO), which can further injure nearby neurons. Activated astrocytes, in turn, contribute to maintaining this neurotoxic environment by releasing additional cytokines and by altering the homeostasis of extracellular ions, such as potassium and glutamate, thus affecting neuronal excitability.

The interplay between microglial and astrocytic activation not only perpetuates the inflammatory response but also supports a feed-forward loop that sustains pain sensitization. This phenomenon is underlined by the release of chemokines like CCL2 and CXCL1, which recruit additional immune cells to the site of injury, amplifying the local inflammatory response. Such a persistent state of glial activation and cytokine release alters the excitability of nociceptive neurons, leading to central sensitization, a hallmark of chronic pain conditions. Central sensitization refers to the increased responsiveness of neurons in the dorsal horn of the spinal cord, which leads to exaggerated pain perception even in response to non-noxious stimuli. This process involves changes at both the transcriptional and post-translational levels in neurons and is sustained by the continuous presence of inflammatory mediators in the spinal cord.

In addition to its role in chronic pain, necroptosis-mediated inflammation has been implicated in the pathogenesis of various neurodegenerative diseases, such as multiple sclerosis (MS), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS). In these conditions, necroptosis contributes to neuronal loss and glial activation, thereby exacerbating disease progression. For instance, in MS, the necroptotic death of oligodendrocytes leads to the release of DAMPs, which attract peripheral immune cells into the CNS and contribute to the demyelination process. Similarly, in AD, necroptosis of neurons can increase the burden of amyloid-beta plaques and tau tangles by perpetuating the inflammatory response through microglial activation. Thus, the involvement of necroptosis in neurodegeneration highlights its dual role as both a mechanism of cell death and a driver of inflammation, underscoring its potential as a therapeutic target.

Given the central role of necroptosis in driving inflammation and cell death, targeting key components of this pathway represents a promising therapeutic strategy. Inhibition of RIPK1 kinase activity has been shown to block necrosome formation and prevent downstream signaling, thereby reducing necroptosis and associated inflammation. Similarly, direct inhibition of MLKL can prevent pore formation at the plasma membrane, thereby preserving cellular integrity. These approaches have potential applications not only in treating chronic pain but also in mitigating the progression of neurodegenerative diseases where necroptosis plays a pathogenic role. Preclinical studies have demonstrated that pharmacological inhibitors of RIPK1, such as necrostatins, can reduce neuroinflammation and improve functional outcomes in models of spinal cord injury and MS. However, the clinical translation of these inhibitors remains a challenge, as systemic inhibition of necroptosis could impair normal immune responses, increasing the risk of infections.

Furthermore, a better understanding of the molecular interactions within the necrosome and the precise mechanisms by which MLKL mediates pore formation may lead to the development of more selective and effective therapeutic agents. Research into the structural biology of RIPK1-RIPK3 complexes and MLKL oligomers is ongoing, providing insights into potential allosteric sites for drug targeting. Combining such approaches with existing anti-inflammatory therapies could offer a synergistic strategy for managing conditions characterized by chronic inflammation and cell death, potentially improving outcomes for patients suffering from chronic pain and neurodegenerative disorders.

The regulation of RIPK1 and RIPK3 through pharmacological inhibitors, such as necrostatins, has been investigated as a strategy to prevent necroptosis and reduce neuroinflammation in neuropathic pain models. Necrostatin-1 (Nec-1), for example, inhibits RIPK1 kinase activity, preventing the formation of the necrosome and thereby blocking the downstream activation of RIPK3 and MLKL. This inhibition has been shown to reduce the inflammatory response and neuronal loss in models of nerve injury, suggesting that targeting necroptosis could be a valuable therapeutic approach for mitigating the progression of neuropathic pain.

3.2. Cross-Talk Between Apoptosis and Necroptosis

The decision between apoptosis and necroptosis is influenced by the activity of key regulators like caspase-8, which can inhibit RIPK1-mediated necroptosis by cleaving RIPK1. When caspase-8 is active, it prevents the formation of the necrosome by disrupting RIPK1 and RIPK3 interactions, thereby favoring apoptotic cell death. This mechanism ensures that apoptosis, a more controlled and non-inflammatory form of cell death, is prioritized under normal conditions. However, when caspase-8 is inhibited, such as during certain inflammatory conditions or in the presence of viral infections, RIPK1 is stabilized, promoting necrosome formation and the induction of necroptosis. This shift towards necroptosis results in a more inflam-

Table 7. Key Regulators of Necroptosis in Neuronal Injury

Regulator	Function in Necroptosis	Mechanism of Action	Therapeutic Targeting
RIPK1	Initiates necrosome formation	Phosphorylates RIPK3, forming a complex that activates MLKL	Necrostatin-1 (Nec-1) can inhibit RIPK1, preventing necroptosis initiation
RIPK3	Amplifies necroptosis signaling	Phosphorylates MLKL, leading to its activation and membrane translocation	Targeting RIPK3 could reduce downstream necroptotic cell death
MLKL	Executes necroptosis	Forms pores in the plasma membrane, leading to cell lysis and DAMP release	Inhibition of MLKL may prevent cell membrane disruption and inflammation

Table 8. Cross-Talk Between Apoptosis and Necroptosis: Key Regulatory Factors

Regulator	Role in Apoptosis/Necroptosis	Effect on Cell Death Pathway Selection	Therapeutic Implications
Caspase-8	Inhibits necroptosis by cleaving RIPK1	Promotes apoptosis when active; loss of function shifts balance towards necroptosis	Targeting caspase-8 can modulate cell death pathway preference in injury contexts
RIPK1	Central mediator of necrosome formation when not cleaved by caspase-8	Stabilizes necrosome and promotes necroptosis in the absence of caspase-8 activity	RIPK1 inhibition (e.g., with Nec-1) can reduce necroptosis and inflammation
FLIP	Regulates caspase-8 activity at death-inducing signaling complexes (DISC)	Modulates sensitivity of cells to apoptotic versus necroptotic death	Enhancing FLIP could favor apoptosis and limit necroptosis

matory form of cell death, contributing to increased tissue damage and the activation of immune responses.

This cross-talk between apoptosis and necroptosis allows cells to switch between a controlled form of cell death (apoptosis) and a more inflammatory form (necroptosis) depending on the extracellular environment and the availability of survival signals. The balance between these pathways is critical in the context of nerve injury, as excessive necroptosis can amplify neuroinflammation and exacerbate pain, while controlled apoptosis may help limit damage by clearing severely injured cells without triggering inflammation.

Understanding the factors that determine the switch between apoptosis and necroptosis in neurons is critical for developing targeted therapies that minimize neuronal loss and inflammation. For example, promoting apoptosis over necroptosis may reduce the release of DAMPs and subsequent neuroinflammatory responses, potentially alleviating the persistence of pain. Conversely, inhibiting apoptosis in situations where necroptosis is favored could help prevent the progression of necroptosis and limit the inflammatory damage. Pharmacological agents that modulate caspase-8 activity or directly target RIPK1 and MLKL offer potential strategies for balancing these cell death pathways to improve outcomes in neuropathic pain.

Necroptosis represents a form of regulated necrosis that contributes to neuronal injury and chronic pain through its promotion of inflammation. The interplay between apoptosis and necroptosis allows cells to adapt their death response to the surrounding environment, influencing the outcome of nerve injury. By targeting the molecular pathways that control these forms of cell death, it may be possible to develop therapies that limit neuroinflammation, preserve neuronal function, and alleviate the debilitating effects of neuropathic pain.

4. Therapeutic Strategies Targeting Apoptosis and Necroptosis

4.1. Caspase Inhibitors and Bcl-2 Modulators

Caspase inhibitors, such as z-VAD-fmk and VX-765, have been explored as potential therapies for reducing apoptosis in models of nerve injury and neuropathic pain. These inhibitors block the activity of initiator and executioner caspases, such as caspase-3, caspase-8, and caspase-9, thereby preventing the dismantling of cellular components and promoting neuronal survival. By inhibiting the caspase cascade, these agents can halt the progression of apoptotic signaling, preserving the structural integrity of neurons and maintaining synaptic connections in regions like the dorsal root ganglia (DRG) and spinal cord. Studies in preclinical models have shown that caspase inhibitors can reduce neuronal loss and alleviate behavioral signs of neuropathic pain, suggesting their potential as neuroprotective agents.

Modulators of the Bcl-2 family, such as BH3 mimetics, have also been investigated to restore the balance between pro-apoptotic and anti-apoptotic signals in neurons, providing protection against mitochondrial-induced apoptosis. BH3 mimetics, like ABT-199 (venetoclax), selectively target Bcl-2 or other anti-apoptotic proteins, thereby freeing pro-apoptotic factors like Bax and Bak to activate controlled cell death when necessary. These agents can be used to fine-tune the apoptotic threshold, ensuring that only severely damaged cells are eliminated while preserving viable neurons. This approach aims to prevent excessive apoptosis that could deplete neuronal populations and contribute to chronic pain while maintaining the normal cellular processes needed for tissue homeostasis.

4.2. Inhibitors of Necroptosis: Targeting RIPK1 and MLKL

Necroptosis inhibitors, such as necrostatins (e.g., Necrostatin-1 or Nec-1), target the kinase activity of RIPK1, preventing the formation of the necrosome and subsequent activation of RIPK3 and MLKL. By

Table 9. Therapeutic Agents Targeting Apoptosis in Neuropathic Pain

Agent	Mechanism of Action	Therapeutic Effects	Challenges
z-VAD-fmk	Broad-spectrum caspase inhibitor; blocks caspase-3, -8, -9 activity	Reduces neuronal apoptosis and preserves synaptic function	May shift cell death towards necroptosis if necroptotic pathways are active
VX-765	Selective inhibitor of caspase-1 and caspase-8	Alleviates pain and reduces inflammation in neuropathic pain models	Requires optimization for effective delivery to nervous tissue
ABT-199 (Venetoclax)	BH3 mimetic; targets Bcl-2 to modulate apoptosis threshold	Provides protection against mitochondrial-induced apoptosis in injured neurons	Risk of unwanted cell death if not carefully controlled

Table 10. Inhibitors Targeting Necroptosis in Neuropathic Pain

Agent	Mechanism of Action	Therapeutic Effects	Challenges
Necrostatin-1 (Nec-1)	Inhibits RIPK1 kinase activity, blocking necrosome formation	Reduces necroptosis and neuroinflammation, protecting neurons from secondary damage	Potential off-target effects and need for specific delivery methods
GSK'872	Selective RIPK3 inhibitor; blocks RIPK3 activation of MLKL	Reduces necroptotic cell death and inflammation in preclinical studies	Effectiveness may vary depending on the specific injury context
NSA (Necrosulfonamide)	Inhibits MLKL pore-forming activity at the plasma membrane	Prevents cell lysis and release of pro-inflammatory DAMPs	Limited data on long-term safety and specificity in humans

blocking necroptosis, these inhibitors reduce the release of damage-associated molecular patterns (DAMPs) and the associated neuroinflammatory response, potentially mitigating pain. Nec-1 has demonstrated efficacy in reducing necroptotic cell death and attenuating the inflammatory responses in animal models of nerve injury. By decreasing the levels of pro-inflammatory cytokines like TNF-α and IL-1β, RIPK1 inhibitors may help to break the cycle of neuroinflammation that sustains chronic pain.

MLKL inhibitors, which prevent the execution of necroptosis by blocking the membrane-disrupting activity of phosphorylated MLKL, have also shown promise in reducing necroptotic cell death and inflammation in preclinical models of neuropathic pain. These inhibitors act downstream of RIPK1 and RIPK3, targeting the final steps of necroptosis where MLKL disrupts membrane integrity. By preventing MLKL-mediated cell lysis, these agents can limit the spread of inflammation to neighboring cells, thereby protecting surrounding neuronal and glial populations from secondary damage. This approach aims to preserve the structural integrity of the neuronal environment and reduce the release of pro-inflammatory DAMPs.

4.3. Combining Anti-Apoptotic and Anti-Necroptotic Approaches

Combining therapies that target both apoptotic and necroptotic pathways may offer a synergistic approach for preserving neuronal integrity and reducing chronic pain. For example, using caspase inhibitors in conjunction with RIPK1 inhibitors may reduce overall neuronal loss while preventing the inflammatory consequences of necroptosis. This dual approach allows for the preservation of neuronal function by preventing excessive apoptosis, while also minimizing the inflammatory damage caused by necroptotic cell death. By simultaneously addressing the multiple mechanisms of cell death, combination therapies can provide a more comprehensive protection of neurons in the dorsal root ganglia and spinal cord.

Tailoring such combination therapies to the specific molecular environment of the injury site is crucial for optimizing their efficacy. For instance, in early stages of nerve injury, therapies may focus more on preventing apoptosis to preserve neuronal populations, while in later stages, reducing necroptosis and its associated inflammation could become more critical. The timing and dosage of these therapies must be carefully adjusted to balance the suppression of cell death with the preservation of necessary cellular functions, avoiding the risk of unintended side effects.

Developing personalized approaches that integrate biomarkers of cell death pathways with therapeutic interventions could enable more precise targeting of apoptosis and necroptosis in individual patients. This would help to ensure that the right balance between cell survival and death is achieved, offering the potential for more effective long-term management of neuropathic pain.

Therapeutic strategies targeting apoptosis and necroptosis offer promising avenues for reducing neuronal loss and controlling the inflammatory environment that sustains chronic pain. By addressing both pathways, it is possible to achieve a more holistic approach to neuroprotection, aiming to preserve neuronal function, minimize inflammation, and ultimately alleviate the persistent pain that characterizes neuropathic conditions.

5. Conclusion

Neuronal apoptosis and necroptosis are key contributors to the progression of neuropathic pain and neuronal degeneration following peripheral nerve injury. While apoptosis serves as a controlled mechanism for eliminating damaged neurons, necroptosis leads to inflammatory cell death that can exacerbate neuroinflammation and pain. The intricate balance between these two forms of cell death determines the extent of neuronal loss and the inflammatory environment within affected neural tissues, such as the dorsal root ganglia (DRG) and spinal cord. As a result, understanding the molecular pathways that regulate apoptosis and necroptosis is crucial for developing effective therapeutic strategies.

Central to these processes are the roles of key regulatory proteins, such as caspases, RIPK1, RIPK3, MLKL, and members of the Bcl-2 family, which mediate the cellular decision between survival and death. Mitochondrial dysfunction and the production of reactive oxygen species (ROS) further amplify apoptotic signaling, while the formation of the necrosome complex drives necroptosis in conditions where caspase activity is inhibited. These mechanisms contribute not only to direct neuronal loss but also to the release of damage-associated molecular patterns (DAMPs) that sustain neuroinflamma-

tion, thereby prolonging pain and sensitizing pain pathways.

Therapeutic interventions targeting these pathways, including caspase inhibitors, necroptosis inhibitors like necrostatins, and modulators of mitochondrial function, offer promising avenues for reducing neuronal loss and mitigating the inflammatory responses associated with chronic pain. By blocking excessive apoptosis, it is possible to preserve viable neurons and maintain synaptic function, while inhibiting necroptosis can prevent the release of inflammatory mediators and reduce the chronic neuroinflammatory state. Such therapies hold potential not only for alleviating pain but also for addressing the underlying neuronal degeneration that characterizes many neuropathic conditions.

Modulating the balance between apoptosis and necroptosis, therefore, represents a strategic approach for mitigating neuronal damage and improving the quality of life for patients suffering from neuropathic conditions. By tailoring treatments to the specific stage of nerve injury and understanding the interplay between these cell death pathways, it may be possible to provide more effective, long-term relief from pain. Further research into the therapeutic potential of these pathways holds promise for advancing the treatment of chronic pain, offering hope for patients who have limited options with current pain management strategies. Ultimately, the integration of apoptosis and necroptosis-targeted therapies with existing pain management approaches could lead to a more holistic and effective treatment paradigm, improving outcomes for individuals living with neuropathic pain. [1]–[26]

References

[1] N. Thompson and W. Evans, "Glutamate signaling and excitotoxicity in neurodegeneration," *Neurobiology of Disease*, vol. 88, pp. 1–9, 2016.

[2] A. Bell and R. Lewis, "The role of ion channels in epilepsy: Mechanisms and potential therapies," *Epilepsy Research*, vol. 116, pp. 95–107, 2015.

[3] D. Shen, W. Wu, J. Liu, *et al.*, "Ferroptosis in oligodendrocyte progenitor cells mediates white matter injury after hemorrhagic stroke," *Cell death & disease*, vol. 13, no. 3, p. 259, 2022.

[4] J. Clark and E. White, *Cellular Pathways in Neurodegeneration: Molecular Insights*, 1st. Berlin, Germany: Springer, 2011.

[5] O. Ford and I. Harris, "Inflammatory pathways in parkinson's disease: The role of microglia," *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, vol. 60, pp. 52–60, 2015.

[6] W. Chen, X. Wang, Q. Sun, *et al.*, "The upregulation of nlrp3 inflammasome in dorsal root ganglion by ten-eleven translocation methylcytosine dioxygenase 2 (tet2) contributed to diabetic neuropathic pain in mice," *Journal of Neuroinflammation*, vol. 19, no. 1, p. 302, 2022.

[7] S. Harrison and J. Davies, "Microglia activation in the pathogenesis of multiple sclerosis," *Frontiers in Neurology*, vol. 3, p. 43, 2012.

[8] P. Howard and A. Cooper, "Mechanisms of cellular stress in neurodegenerative diseases," *Cell Stress & Chaperones*, vol. 21, no. 5, pp. 709–720, 2016.

[9] Y. Ding, L. Hu, X. Wang, *et al.*, "The contribution of spinal dorsal horn astrocytes in neuropathic pain at the early stage of eae," *Neurobiology of Disease*, vol. 175, p. 105 914, 2022.

[10] D. Knight and M. Foster, *Cell Signaling in Neurological Disorders*, 2nd. New York, NY, USA: Wiley, 2014.

[11] K. Mason and J. Taylor, "Therapeutic approaches targeting synaptic dysfunction in autism," in *Proceedings of the International Conference on Neuroscience*, Paris, France, 2013, pp. 89–96.

[12] Q. Sun, T. Hu, Y. Zhang, *et al.*, "Irg1/itaconate increases il-10 release to alleviate mechanical and thermal hypersensitivity in mice after nerve injury," *Frontiers in Immunology*, vol. 13, p. 1 012 442, 2022.

[13] E. Murphy and H. Scott, "The role of mitochondrial dynamics in parkinson's disease," *Molecular Neurobiology*, vol. 49, no. 3, pp. 945–957, 2014.

[14] M. King and L. Bennett, "Oxidative stress in neurodegenerative diseases: Mechanisms and therapeutic strategies," *Brain Research Bulletin*, vol. 95, pp. 1–13, 2013.

[15] T. Russell and S. Gray, "Autophagy dysregulation in huntington's disease: Mechanisms and interventions," *Nature Neuroscience*, vol. 15, no. 10, pp. 1317–1325, 2012.

[16] T. Hu, Q. Sun, Y. Gou, *et al.*, "Salidroside alleviates chronic constriction injury-induced neuropathic pain and inhibits of txnip/nlrp3 pathway," *Neurochemical Research*, pp. 1–10, 2022.

[17] E. Stewart and J. Lee, "Mechanisms of synaptic degeneration in alzheimer's and parkinson's diseases," *Journal of Molecular Neuroscience*, vol. 50, no. 2, pp. 193–204, 2013.

[18] J. Liu, D. Shen, C. Wei, *et al.*, "Inhibition of the lrrc8a channel promotes microglia/macrophage phagocytosis and improves outcomes after intracerebral hemorrhagic stroke," *Iscience*, vol. 25, no. 12, 2022.

[19] M. Phillips and V. Edwards, "Neuroinflammation and tau pathology in alzheimer's disease," *Journal of Neuroinflammation*, vol. 11, p. 102, 2014.

[20] R. Walker and T. Hughes, "Endoplasmic reticulum stress in neuronal injury and repair," *Journal of Cellular Neuroscience*, vol. 42, no. 1, pp. 57–68, 2010.

[21] W. Chen, T. Lan, Q. Sun, *et al.*, "Whole genomic dna methylation profiling of cpg sites in promoter regions of dorsal root ganglion in diabetic neuropathic pain mice," *Journal of Molecular Neuroscience*, vol. 71, no. 12, pp. 2558–2565, 2021.

[22] L. Wright and S. Williams, "Advances in understanding glial cell function in cns disorders," in *Annual Conference of the European Society for Neuroscience*, Madrid, Spain, 2011, pp. 45–52.

[23] C. Wei, Z. Xiao, Y. Zhang, *et al.*, "Itaconate protects ferroptotic neurons by alkylating gpx4 post stroke," *Cell Death & Differentiation*, pp. 1–16, 2024.

[24] R. Young and C. Morgan, "Calcium dysregulation in als: Pathophysiology and therapeutic approaches," *Neuroscience*, vol. 278, pp. 1–12, 2014.

[25] E. Clarkson and G. Adams, "Protein misfolding and aggregation in amyotrophic lateral sclerosis," *Neurotherapeutics*, vol. 13, no. 3, pp. 624–632, 2016.

[26] C. Watson and H. Mitchell, *Fundamentals of Neurodegenerative Diseases: A Molecular Perspective*, 1st. Boca Raton, FL, USA: CRC Press, 2012.